Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 09:24 pm
Share
Vivos Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 3.3 million compared to USD 4.25 million a year ago. Net loss was USD 2.09 million compared to USD 5.43 million a year ago. Basic loss per share from continuing operations was USD 1.75 compared to USD 6.4 a year ago.
For the nine months, revenue was USD 10.55 million compared to USD 12.07 million a year ago. Net loss was USD 9.32 million compared to USD 17.76 million a year ago. Basic loss per share from continuing operations was USD 8.09 compared to USD 20.9 a year ago.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.